CHINA PHARMA HOLDINGS, INC. Repayments of Lines of Credit
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Repayments of Lines of Credit of $79.97 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLinesOfCredit · last filed 2026-08-14
- CHINA PHARMA HOLDINGS, INC. repayments of lines of credit for the quarter ending 2026-06-30 was $645.00, a 99.94% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. repayments of lines of credit for the quarter ending 2026-03-31 was $79.33K, a 3.26% increase year-over-year.
- CHINA PHARMA HOLDINGS, INC. repayments of lines of credit for the quarter ending 2025-12-31 was $701.41K.
- CHINA PHARMA HOLDINGS, INC. repayments of lines of credit for the quarter ending 2025-09-30 was -$617.96K.
- CHINA PHARMA HOLDINGS, INC. repayments of lines of credit for fiscal 2025 was $1.18M, a 138.72% increase from fiscal 2024.
- CHINA PHARMA HOLDINGS, INC. repayments of lines of credit for fiscal 2024 was $492.76K, a 66.93% decline from fiscal 2023.
- CHINA PHARMA HOLDINGS, INC. repayments of lines of credit for fiscal 2023 was $1.49M, a 30.40% decline from fiscal 2022.
- CHINA PHARMA HOLDINGS, INC. repayments of lines of credit for fiscal 2022 was $2.14M, a 15.26% decline from fiscal 2021.
| Period end | Repayments of Lines of Credit 0 month | Repayments of Lines of Credit 3 month | Repayments of Lines of Credit 6 month | Repayments of Lines of Credit 9 month | Repayments of Lines of Credit 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $645.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $79.97K 10-Q · filed 2026-08-14 | $781.38K derived: sum of 3 quarters · filed 2026-08-14 | $163.42K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $79.33K 10-Q · filed 2026-05-15 | $780.74K derived: sum of 2 quarters · filed 2026-05-15 | $162.78K derived: sum of 3 quarters · filed 2026-05-15 | $1.18M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $701.41K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $83.45K derived: sum of 2 quarters · filed 2026-04-01 | $1.10M derived: sum of 3 quarters · filed 2026-08-14 | $1.18M 10-K · filed 2026-04-01 | |
| 2025-09-30 | -$617.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $398.11K derived: sum of 2 quarters · filed 2026-08-14 | $474.93K 10-Q · filed 2025-11-12 | $474.93K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.09M 10-Q · filed 2026-08-14 | $1.09M derived: sum of 3 quarters · filed 2026-08-14 | $1.09M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $76.82K 10-Q · filed 2026-05-15 | $76.82K derived: sum of 2 quarters · filed 2026-05-15 | $76.82K derived: sum of 3 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $0.00 derived: sum of 2 quarters · filed 2026-04-01 | $492.76K 10-K · filed 2026-04-01 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $492.76K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $492.76K 10-Q · filed 2025-08-14 | ||||
| 2023-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.49M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $456.18K 10-Q · filed 2024-11-13 | ||||
| 2022-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.23M derived: sum of 2 quarters · filed 2024-04-01 | $2.09M derived: sum of 3 quarters · filed 2024-04-01 | $2.14M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$16.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $845.78K derived: sum of 2 quarters · filed 2023-11-13 | $893.02K 10-Q · filed 2023-11-13 | $978.06K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $862.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $910.00K 10-Q · filed 2022-08-11 | $995.04K derived: sum of 3 quarters · filed 2022-08-11 | $2.54M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2022-03-31 | $47.24K 10-Q · filed 2022-05-12 | $132.28K derived: sum of 2 quarters · filed 2022-05-12 | $1.68M derived: sum of 3 quarters · filed 2022-11-14 | $2.53M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-12-31 | $85.04K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $1.63M derived: sum of 2 quarters · filed 2022-11-14 | $2.48M derived: sum of 3 quarters · filed 2022-11-14 | $2.53M 10-K · filed 2022-03-30 | |
| 2021-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.40M derived: sum of 2 quarters · filed 2022-11-14 | $2.44M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $849.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $896.19K 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $46.27K 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $72.49K 10-K · filed 2022-03-30 | ||||
| 2016-10-19 | $2.25M 10-K · filed 2018-04-02 | ||||
| 2016-09-16 | $2.25M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |